Oncolytic Virus Plus Chemo Nearly Doubles 18-Month Survival in Pancreatic Cancer
A randomized phase 2b trial shows a hyaluronidase-expressing oncolytic adenovirus added to standard chemotherapy significantly improves survival in metastatic pancreatic cancer.
Summary
Pancreatic ductal adenocarcinoma remains one of the deadliest cancers, with few effective first-line options. This randomized phase 2b trial tested VCN-01, an oncolytic adenovirus engineered to express hyaluronidase — an enzyme that breaks down the dense tumor matrix — combined with standard gemcitabine and nab-paclitaxel chemotherapy. In the primary analysis population, median overall survival improved from 8.6 to 10.8 months, and progression-free survival jumped from 4.6 to 7.0 months. Most strikingly, 18-month survival rates were 31.1% versus 8.5%, suggesting a meaningful tail benefit. Duration of tumor response was more than doubled. Two doses given 14 weeks apart provided the greatest benefit, with evidence of ongoing viral replication despite neutralizing antibodies. Side effects were manageable and notably milder after the second dose.
Detailed Summary
Pancreatic ductal adenocarcinoma (PDAC) is notorious for its dense, immunosuppressive stroma and dismal prognosis — median survival on standard chemotherapy hovers below 12 months. Novel approaches that can penetrate the tumor microenvironment and enhance treatment delivery are urgently needed. VCN-01, now designated zabilugene almadenorepvec, is a genetically engineered oncolytic adenovirus that replicates selectively in tumor cells and simultaneously secretes hyaluronidase, an enzyme that degrades the hyaluronic acid-rich extracellular matrix surrounding pancreatic tumors. By breaking down this barrier, VCN-01 is designed to improve both viral spread within the tumor and chemotherapy penetration.
This international, randomized phase 2b trial enrolled patients with treatment-naive metastatic PDAC. Participants received either VCN-01 intravenously combined with gemcitabine and nab-paclitaxel (GnP), or GnP alone. The primary endpoint was overall survival (OS). In the full analysis set of 48 patients per arm, median OS improved from 8.6 to 10.8 months (HR 0.57; P = 0.055), meeting the pre-specified primary endpoint threshold. Progression-free survival improved significantly from 4.6 to 7.0 months (HR 0.55; P = 0.011).
The most dramatic finding was the long-term survival benefit. At 15 months, 35.5% of VCN-01-treated patients were alive versus 12.8% in the control arm; at 18 months, the figures were 31.1% versus 8.5%. Duration of response was more than doubled (11.2 versus 5.4 months; HR 0.22; P = 0.004). Patients who received two VCN-01 doses 14 weeks apart showed the strongest benefit, with circulating viral genomes detectable at the time of the second dose, confirming continued viral replication and preserved bioactivity despite the presence of neutralizing antibodies.
Safety was an important consideration. VCN-01-related adverse events included fever, flu-like symptoms, elevated liver enzymes, and reduced platelet counts. Serious events occurred in 22.6% of VCN-01-treated patients, but the second dose was better tolerated than the first. Two fatal events occurred — one per arm — neither attributed to study treatment.
These results represent a meaningful advance in a cancer with few therapeutic breakthroughs. The phase 2b data support progression to a blinded phase 3 trial. Limitations include the open-label design, modest sample size, and that this summary is based on the abstract only, so full subgroup analyses and biomarker data are not yet available for review.
Key Findings
- 18-month survival was 31.1% with VCN-01 plus chemo versus 8.5% with chemo alone — nearly a fourfold difference.
- Progression-free survival improved significantly from 4.6 to 7.0 months (HR 0.55, P = 0.011) in the primary analysis group.
- Duration of tumor response more than doubled: 11.2 versus 5.4 months (HR 0.22, P = 0.004).
- Two VCN-01 doses 14 weeks apart provided the greatest benefit, with viral replication persisting despite neutralizing antibodies.
- The second dose was better tolerated than the first, suggesting an adaptive immune accommodation to the virus.
Methodology
This was an open-label, randomized phase 2b trial conducted across multiple sites in Spain and the United States. Patients with treatment-naive metastatic PDAC were randomized to intravenous VCN-01 plus gemcitabine and nab-paclitaxel or chemotherapy alone. Primary endpoints were OS in the intent-to-treat and full analysis set populations, with safety assessed separately.
Study Limitations
The trial was open-label and relatively small (approximately 100 patients total), which limits the statistical power of the primary OS endpoint, which only narrowly missed significance in the intent-to-treat population. Biomarker correlates, full subgroup analyses, and quality-of-life data are not available from the abstract alone. This summary is based on the abstract only, as the full paper is not open access.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: